AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01314105
Drug: BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBF1120 twice daily along with standard therapy of PLD + carboplatin
Trial: NCT01314105
Drug: BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBF1120 twice daily along with standard therapy of PLD + carboplatin
Trial: NCT02179866
Drug: RO5285119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of RO5285119 with approximately 2.1 MBq (56.6 uCi) \[14C\]-radiolabeled RO5285119 administered as a drinking solution under fasted conditions on Day -1
Trial: NCT02632331
Drug: ASP8825
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01934023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03928496
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were injected with 0.1 ml of preservative free normal saline into 31 distinct muscle locations in the head and neck
Trial: NCT02019693
Drug: INC280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied by Novartis as film-coated tablet for oral use.
Trial: NCT04046094
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic Acid Intravenous
Trial: NCT03083171
Drug: Endotoxin
RxNorm normalized name: Endotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At T=0 1 ng/kg E. Coli type O113 lipopolysaccharide is administrated intravenously as a bolus, followed by 1 ng/kg/hour for 3 hours.
Trial: NCT03083171
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At T=1 hour, placebo will be administered intravenously over a 1 hour period. Placebo is indistinguishable from Adrecizumab.
Trial: NCT01500577
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg (capsules). 20mg/die every day for 1 year. Oral administration
Trial: NCT01826188
Drug: THC 5mg/ml and CBS 50mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olive oil containing THC and CBD
Trial: NCT01826188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olive oil without cannabis
Trial: NCT02238145
Drug: Atrovent® Inhaletten
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00332163
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
Trial: NCT00332163
Drug: Pre-emptive Skin Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-emptive skin treatment included a skin moisturizer (eg, Lubriderm), sunscreen (free of paraaminobenzoic acid (PABA), skin protection factor (SPF) 15 or higher, ultraviolet-A (UV-A), and UV-B protection), topical steroid (1% hydrocortisone cream) and oral antibiotic (doxycycline, 100 mg twice daily).
Trial: NCT00332163
Drug: Reactive Skin Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment was based on symptoms and severity and may have included an emollient (eg, Lubriderm, Vaseline), sunscreen (SPF ≥ 15), oral antibiotic (eg, doxycycline, ciprofloxacin, cefadroxil, amoxicillin/clavulanic acid), topical steroid (hydrocortisone cream), topical antibiotic (clindamycin), oral systemic steroid, topical medical treatment (eg, silver sulfadiazine, Silvadene), topical antihistamine or oral antihistamine (hydroxyzine)
Trial: NCT03478657
Drug: Placebo DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo via oral inhalation route using ELLIPTA once daily. Placebo DPI will be available in two strips of 30 blisters per strip. First strip will contain lactose monohydrate and second strip will have lactose monohydrate blended with magnesium stearate.
Trial: NCT04201093
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
Trial: NCT01345045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 6 weeks.
Trial: NCT01622998
Drug: Nicorette Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorette Inhaler: Box, 42 cartridges (4mg/cartridge) Dosage: Ad libitum Maximum dosage: 6-12 cartridges/day
Trial: NCT03677648
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).
Trial: NCT03677648
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos
Trial: NCT00981357
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg tablet twice daily / matched placebo
Trial: NCT01561274
Drug: 1.5 ml bupivicaine.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml bupivicaine.
Trial: NCT02693210
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive 750 mg infusions of cyclophosphamide on Days 3 and 17
Trial: NCT02693210
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive \>= 10 mg/week methotrexate orally up to 24 weeks
Trial: NCT02502110
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All recruited patients with paroxysmal atrial fibrillation will be randomly allocated to receive oral rosuvastatin 20mg/day or blank control from 7 days before ablation and last for 3 months.
Trial: NCT03018366
Drug: 17beta Estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will use a dose of transdermal estradiol 0.1 mg/day patch for 12 weeks +/- 1week. PAT index vascular measures and serum immune markers will be measured after 6 and 12 weeks +/- 1week on estrogen patches. Patches will be applied by the participant to the lower abdomen twice weekly, alternating sides.
Trial: NCT03018366
Drug: Placebo Pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 12 weeks +/- 1week of transdermal placebo patch, participants will use placebo patch plus placebo pill for 2 additional weeks +/- 3 days.
Trial: NCT00559481
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02899338
Drug: BI695501 Prefilled syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02899338
Drug: BI695501Autoinjector
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01786668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 blinded tablets (two 1 mg and two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
Trial: NCT00006734
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01591759
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm of single-blind study
Trial: NCT00006734
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04561466
Drug: Béfizal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mf befizal a day for one year
Trial: NCT02242292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03675477
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a Janus kinase inhibitor).
Trial: NCT03675477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet
Trial: NCT01251237
Drug: NRL0706
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive 1 litre of NRL0706 solution followed by 0.5 litre of clear liquid during the afternoon/evening prior to colonoscopy. Patients receive 1 litre of 0706 solution followed by 0.5 litre of clear liquid during the morning of colonoscopy.
Trial: NCT00302952
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
Trial: NCT00302952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
Trial: NCT01245322
Drug: lactobacilli
RxNorm normalized name: lactobacillic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: women were given a seven days course of daily 2% vaginal clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral clindamycin 300 mg BID for 7 days (Dalacin 300 mg, Pfizer Norway Ltd). Oral clindamycin treatment was also given to the patient's sexual partner.
Trial: NCT01849783
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01849783
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT02126995
Drug: MG01CI extended-release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metadoxine, MG01CI extended-release tablet taken for 6 weeks treatment. Starting with a dose of 700 mg for 2 weeks followed by a 2 weeks of 1400 mg and then 2 weeks of 700 mg or 1400 mg.
Trial: NCT00406848
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 13 weeks (The first week was placebo lead-in). This double-blind acute phase was followed by a double-blind 12 week continuation phase during which participants either remained on placebo or were eligible for receiving duloxetine 60 milligrams (mg) orally once daily (QD), beginning with duloxetine 30 mg QD orally for 1 week followed by duloxetine 60 mg QD orally for the remainder of the study based on depression symptom severity.
Trial: NCT02796469
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02796469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02143466
Drug: Part B - AZD9291 in combination with AZD6094
RxNorm normalized name: haemophilus influenzae B, combinations with toxoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B - AZD9291 and AZD6094 administered in the dose identified in Part A (AZD9291 80mg OD + AZD6094 600mg OD) to further investigate the safety and tolerability of this combination.
Trial: NCT03392909
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term intravenous gentamicin therapy should have the advantage of treating all of the patient's multiple skin wounds simultaneously. Six patients (three adults and 3 children) will receive intravenous gentamicin (7.5 mgs/kg) daily for 14 days and then stopped. Three adult patients will receive intravenous gentamicin (7.5mg/kg) biweekly for three months and then stopped.
Trial: NCT02143466
Drug: Part B - AZD9291 in combination with MEDI4736
RxNorm normalized name: haemophilus influenzae B, combinations with toxoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B - AZD9291 and MEDI4736 administered in the dose identified in Part A to further investigate the safety and tolerability of this combination.~Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study.
Trial: NCT02143466
Drug: Part C - AZD9291 in combination with AZD6094 (Japan only)
RxNorm normalized name: vitamin C combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part C combination cohort - AZD9291 80mg OD administered in combination with AZD6094 400mg OD (AZD6094 dose in which DLTs have not been identified in the Japanese monotherapy cohort) in order to confirm the safety, tolerability, pharmacokinetics and preliminary anti-tumor activities of this combination in Japanese subjects. The 400mg OD dosing schedule will be initiated in the first cohort. The dose may be subsequently reduced in further cohorts in response to emerging safety, or PK findings or other reasons identified in the savolitinib programme.
Trial: NCT02143466
Drug: Part D - AZD9291 in combination with AZD6094
RxNorm normalized name: Calcium, combinations with vitamin D and/or other drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part D - AZD9291 80mg OD administered in combination with AZD6094 300mg OD to further evaluate the safety, tolerability, pharmacokinetics and antitumor activity in terms of ORR and PFS in patients with locally advanced or metastatic cMET positive EGFRm+ and T790M-negative NSCLC, following progression on EGFR-TKI treatment. The choice of AZD6094 dose of 300 mg is based on results from preclinical and clinical studies. Clinical testing of the 300 mg OD dose will enable better assessment of impact of lower AZD6094 exposure on overall tolerability and hepatotoxicity risk as well as exploration of the efficacy and overall safety profiles with a dose meaningfully lower than the current dose of 600 mg OD.
Trial: NCT04314726
Drug: Amelogenin
RxNorm normalized name: amelogenin protein matrix, porcine derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amelogenins applied on the distal surface of the lower second molar after adjacent third molar extraction
Trial: NCT04314726
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo applied on the distal surface of the lower second molar after adjacent third molar extraction
Trial: NCT03694587
Drug: Ibuprofen 200 mg TEPI Medicated Plaster
RxNorm normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 200mg TEPI medicated plaster applied to the upper back daily for 24 hours for 5 days
Trial: NCT03694587
Drug: Aktren® 200 mg überzogene Tabletten (Ibuprofen)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one dose of Aktren® 200 mg überzogene Tabletten (Ibuprofen tablet)
Trial: NCT03920007
Drug: 1% Prednisolone
DrugBank: Prednisolone (DB00860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Suspension Route of administration: Drops
Trial: NCT00163449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02051309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01718938
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02528760
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin to be given 70mg iv 12 hourly.
Trial: NCT00740389
Drug: TMC125
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02984111
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04258163
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000-1250 mg/m 2 PO twice daily days 1-14, cycled every 28 days
Trial: NCT04258163
Drug: Liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m 2 IV day 1, cycled every 28 days
Trial: NCT03633890
Drug: DaZhu Rhodiola Rosea Capsule
RxNorm normalized name: RHODIOLA ROSEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, 4 capsules, 3 times a day, for 8 weeks
Trial: NCT03633890
Drug: DaZhu Rhodiola Rosea Simulation Capsule
RxNorm normalized name: RHODIOLA ROSEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, 4 capsules, 3 times a day, for 8 weeks
Trial: NCT03654196
Drug: HL301(Experimental)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total 7 days of treatment and The daily dose is as follows \[Morning: HL301 1Tab + Placebo of Umkamin 1Tab\] \[Noon: Placebo of Umkamin 1Tab\] \[Evening: HL301 1Tab + Placebo of Umkamin 1Tab\]
Trial: NCT04814745
Drug: Intravenous Infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tramadol administration
Trial: NCT03155048
Drug: Estradiol transdermal patch
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: transdermal estradiol group for endometrial preparation
Trial: NCT00002725
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03830125
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to BBT-877, oral capsule
Trial: NCT00714103
Drug: 8-Chloro-Adenosine
RxNorm normalized name: 2-chloro-2'-deoxy-adenosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg/m\^2 intravenous over 1 hour daily for 5 days every 4 weeks (± 3 days).
Trial: NCT03092453
Drug: Cyclophosphamide 300mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered prior to subject's first DC dose
Trial: NCT01999179
Drug: Heparin, Low-Molecular-Weight, or direct oral anticoagulants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing obtained by the clinical team or either apixaban, rivaroxaban, dabigatran, edoxaban following a catheter related blood clot
Trial: NCT02927509
Drug: TNF alpha blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002554
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002554
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04505033
Drug: HB0017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB0017 at 100 mg/mL (1 mL/vial) in 2 mL glass vial with a rubber stopper. HB0017 will be administered in the abdominal area by a subcutaneous injection in the mornings. A maximum volume of 1 mL is injected per site.
Trial: NCT04505033
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matching injection solution containing a specific volume of normal saline (0.9%, Sodium Chloride Injection USP) and no active substance will be prepared for the subjects who will be assigned to placebo according to the dose schedule.
Trial: NCT01452451
Drug: HM11260C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1, 2, and 4 mg for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. 8, 12 and 16 mg for 3 monthly subcutaneous injections for cohorts M1, M2 and M3
Trial: NCT01452451
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. Placebo for 3 monthly subcutaneous injections for for cohorts M1, M2 and M3
Trial: NCT00419770
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04500470
Drug: Ketoprofen + INH
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table 900 mg vaginal isonicotinic acid hydrazide by the patient 12 hours before the procedure
Trial: NCT04500470
Drug: Ketoprofen + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table placebo by the patient 12 hours before the procedure
Trial: NCT02033109
Drug: PC-1005
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal use
Trial: NCT02033109
Drug: HEC gel
RxNorm normalized name: ALCOHOL 73 L in 100 L TOPICAL GEL [Grand Valley Reagents HEC Hand Sanitizer Gel]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00152282
Drug: Placebo and Premarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
Trial: NCT01494506
Drug: 5 Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B: 5 Fluorouracil 2000 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: 5 Fluorouracil 2400 mg/m2 IV every 2 weeks
Trial: NCT01494506
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm B: Leucovorin 200 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: Leucovorin 400 mg/m2 IV every 2 weeks
Trial: NCT03456570
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets twice daily
Trial: NCT01581970
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be given oral cyclophosphamide 50 mg twice daily to be self-administered starting the first day of therapy with weekly cetuximab for 12 weeks or until disease progression.
Trial: NCT02339584
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredients used as a placebo for masking purposes
Trial: NCT03282643
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 ml once daily, before femoral venepuncture(day1) and the following day (day 2)